Livmarli (maralixibat) now approved for progressive familial intrahepatic cholestasis in patients 12 months and older
Mirum Pharmaceuticals, Inc. announced that the FDA has approved a label expansion for Livmarli (maralixibat) oral solution for the treatment of cholestatic pruritus in patients with progressive familial intrahepatic cholestasis (PFIC)
The expanded label includes use in PFIC patients 12 months and older as well as the higher concentration formulation of Livmarli evaluated in the MARCH Phase III study.
“The launch of Livmarli in PFIC is going well and we are thrilled that it will now be available for patients 12 months and older,” said Chris Peetz, chief executive officer at Mirum. “PFIC is generally diagnosed when children are young, and initiating treatment quickly after diagnosis will help to ensure they have fewer days suffering from pruritus associated with this rare liver disease.”
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
2 mins